Learn more about Claudio’s recap of 2022 at GenomSys and his outlook for 2023 for himself and the company through the following quick questions:
Good morning and happy New Year Claudio. What was your most outstanding achievement at GenomSys in 2022?
We finalized our platform’s first end-to-end complete version of for efficient genome sequencing data processing from MPEG-G coding of raw sequencing data to report generation. This is an outstanding achievement to show our customers the level of automation and speed reachable by using MPEG-G as a single data and metadata representation format for genome sequencing information. The flexibility and modularity of the platform enabled us to rapidly implement and integrate the first working version of our Blood Genotyper able to characterize more than 40 different blood group systems from Next-Generation Sequencing (NGS) data.
Then we improved the efficiency of our data analysis software to support variant calling on whole genomes, even on mobile devices. We are now ready to offer genomic data storage and analysis on mobile devices for various services, from nutrigenomics to pharmacogenomics and risk assessment.
What was the most important thing you learned in 2022?
In the next few years, genomics will change the way we look at our health and quality of life in many more ways than expected. The accompanying data generation – outgrowing traditional methods to process digital information – will put a barrier that inhibits the full exploitation of the potential that the information within our DNA has to help patients in need.
What are your expectations for you and/or GenomSys for 2023?
We are going to launch several first-of-their-kind genomic analysis services both for clinical and lifestyle purposes. In order to make our promise become a reality of accelerating personalized genomics.
If you have any further questions for Claudio or about GenomSys, please feel free to contact us.
